Canada’s Valeant Pharmaceuticals divides opinion in the investment world. To some it’s the whip-smart upstart feasting on the bloated and bumbling big pharma sector, while to others it’s a rapacious predator, or even a roll-up vehicle that will eventually crash to Earth. But what’s staid and sensible AstraZeneca (LSE: AZN) doing making deals with it?
The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.
You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.
AstraZeneca plc In New Partnership With Controversial Valeant Pharmaceuticals Intl Inc
VIDEO: One Fool takes a closer look at AstraZeneca plc (LON:AZN) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX).
You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.